161 related articles for article (PubMed ID: 10699539)
41. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.
Dranitsaris G; Maroun J; Shah A
Can J Gastroenterol; 2005 Feb; 19(2):83-7. PubMed ID: 15729427
[TBL] [Abstract][Full Text] [Related]
42. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Gibson RJ; Bowen JM; Keefe DM
Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
[TBL] [Abstract][Full Text] [Related]
43. Visual diagnosis: Chronic diarrhea and failure to thrive in a 5-year-old girl.
Hasosah M; Satti M; Hayat A
Pediatr Rev; 2014 Jun; 35(6):e29-31. PubMed ID: 24891601
[TBL] [Abstract][Full Text] [Related]
44. Irinotecan toxicity.
Anthony L
Curr Opin Support Palliat Care; 2007 Apr; 1(1):35-9. PubMed ID: 18660722
[TBL] [Abstract][Full Text] [Related]
45. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions.
Byun HJ; Yang JI; Kim BK; Cho KH
J Am Acad Dermatol; 2011 Oct; 65(4):726-732. PubMed ID: 21641677
[TBL] [Abstract][Full Text] [Related]
46. Infliximab for steroid-refractory acute GVHD: a case series.
Jacobsohn DA; Hallick J; Anders V; McMillan S; Morris L; Vogelsang GB
Am J Hematol; 2003 Oct; 74(2):119-24. PubMed ID: 14508798
[TBL] [Abstract][Full Text] [Related]
47. [Management and types of side effects in chemotherapy for lung cancer].
Yoshida K
Nihon Rinsho; 2002 May; 60 Suppl 5():384-7. PubMed ID: 12101694
[No Abstract] [Full Text] [Related]
48. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life.
Tarricone R; Abu Koush D; Nyanzi-Wakholi B; Medina-Lara A
Crit Rev Oncol Hematol; 2016 Mar; 99():37-48. PubMed ID: 26775731
[TBL] [Abstract][Full Text] [Related]
49. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.
Abd El-Atti S; Wasicek K; Mark S; Hegazi R
JPEN J Parenter Enteral Nutr; 2009; 33(5):569-70. PubMed ID: 19423769
[TBL] [Abstract][Full Text] [Related]
50. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study.
Yavuz MN; Yavuz AA; Aydin F; Can G; Kavgaci H
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):195-202. PubMed ID: 12182992
[TBL] [Abstract][Full Text] [Related]
51. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
Gebbia V; Carreca I; Testa A; Valenza R; Curto G; Cannata G; Borsellino N; Latteri MA; Cipolla C; Florena M
Anticancer Drugs; 1993 Aug; 4(4):443-5. PubMed ID: 8400346
[TBL] [Abstract][Full Text] [Related]
52. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin.
Cascinu S; Fedeli A; Fedeli SL; Catalano G
Oncology; 1994; 51(1):70-3. PubMed ID: 8265106
[TBL] [Abstract][Full Text] [Related]
53. The gastrointestinal complications of oncologic therapy.
Shafi MA; Bresalier RS
Gastroenterol Clin North Am; 2010 Sep; 39(3):629-47. PubMed ID: 20951921
[TBL] [Abstract][Full Text] [Related]
54. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
Maroun JA; Anthony LB; Blais N; Burkes R; Dowden SD; Dranitsaris G; Samson B; Shah A; Thirlwell MP; Vincent MD; Wong R
Curr Oncol; 2007 Feb; 14(1):13-20. PubMed ID: 17576459
[TBL] [Abstract][Full Text] [Related]
55. Treatment-related diarrhea in patients with cancer.
Shaw C; Taylor L
Clin J Oncol Nurs; 2012 Aug; 16(4):413-7. PubMed ID: 22842693
[TBL] [Abstract][Full Text] [Related]
56. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Keefe DM; Elting LS; Nguyen HT; Grunberg SM; Aprile G; Bonaventura A; Selva-Nayagam S; Barsevick A; Koczwara B; Sonis ST
Cancer Chemother Pharmacol; 2014 Oct; 74(4):675-80. PubMed ID: 25055935
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation.
Yamada-Fujiwara M; Miyamura K; Fujiwara T; Tohmiya Y; Endo K; Onishi Y; Ishizawa K; Kameoka J; Ito M; Harigae H
Tohoku J Exp Med; 2012 May; 227(1):31-7. PubMed ID: 22531159
[TBL] [Abstract][Full Text] [Related]
58. Etiology and outcome of diarrhea after marrow transplantation: a prospective study.
Cox GJ; Matsui SM; Lo RS; Hinds M; Bowden RA; Hackman RC; Meyer WG; Mori M; Tarr PI; Oshiro LS
Gastroenterology; 1994 Nov; 107(5):1398-407. PubMed ID: 7926504
[TBL] [Abstract][Full Text] [Related]
59. Management of chemotherapy-induced diarrhea and constipation.
Cope DG
Nurs Clin North Am; 2001 Dec; 36(4):695-707, vi. PubMed ID: 11726348
[TBL] [Abstract][Full Text] [Related]
60. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
